Personalized timing based on assessment of mutant BRAF or KRAS amplification levels by sampling cfDNA for example, may be required to better elicit MAPK hyperactivation to forestall drug resistance using an intermittent dosing strategy in lung and melanoma patients. Here, KRAS is linked to melanoma.